- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00254384
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Study Overview
Status
Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the safety/toxicity of neoadjuvant chemotherapy with cisplatin and docetaxel followed by maintenance therapy with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (erlotinib hydrochloride) in patients with stage I-III non-small cell lung cancer (NSCLC) undergoing definitive treatment with surgery and/or radiation.
II. To estimate the agreement in baseline to post-treatment changes of EGFR expression (i.e., EGFR modulation) between buccal smears and bronchial tissue.
SECONDARY OBJECTIVES:
I. To evaluate the disease free survival of this therapeutic combination. II. To assess overall quality of life. III. To evaluate predictive biomarkers in early-stage NSCLC.
OUTLINE:
Patients receive docetaxel intravenously (IV) over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride orally (PO) daily for up to 1 year.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 4 years.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed diagnosis of stage I, II or III non-small cell lung cancer; tissue blocks or slides will be requested
- Patients must have surgically resectable disease and may not be treated with prior chemotherapy or radiation
- Patients must be able to tolerate systemic chemotherapy prior to surgical resection
- No acute intercurrent illness or infection
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Leukocytes >= 3,000/uL
- Absolute neutrophil count (ANC) >= 1,500/uL
- Platelets >= 100,000/uL
- Hemoglobin >= 8g/dL
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Bilirubin within normal institutional limits
- Alkaline phosphatase (alk phos) =< 2.5 x upper limit of normal (ULN); if alk phos > 2.5 x ULN but =< 5 x ULN, patient is eligible if AST or ALT =< ULN
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x ULN; if AST or ALT > 1.5 x ULN but =< 5 x ULN, patient is eligible if alk phos is =< ULN
- Prior to study enrollment, all women of child-bearing potential must have a negative pregnancy test; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 2 months after the completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Patients with a history of non-melanoma skin cancer, or other malignancies treated 5 years or more prior to the current tumor, from which the patient has remained continually disease-free, are eligible
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had prior chemotherapy or radiotherapy for lung cancer
- Patients may not be receiving any other investigational agents within 30 days of trial entry, including anti-EGFR drugs
- Patient has signs or symptoms of acute infection requiring systemic therapy
- Patient exhibits confusion, disorientation, or has a history of major psychiatric illness that may impair patient's understanding of the informed consent
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Functional Classification class II or worse), unstable angina pectoris, serious or clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients refusing to sign the informed consent
- Patients with pre-existing peripheral neuropathy National Cancer Institute (NCI) Common Toxicity Criteria (CTC) grade 2 or worse
- Patients must not be pregnant or breast-feeding and all (male and female) must use a contraceptive method deemed acceptable by the investigator while receiving active treatment in the study and for up to two months following completion of therapy
- Patients with a history of severe hypersensitivity reaction to Taxotere and or polysorbate 80 must be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (docetaxel, cisplatin, erlotinib hydrochloride)
Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1.
Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride PO daily for up to 1 year.
|
Given PO
Other Names:
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
Given PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of grade 3 or greater toxicities (hematologic or non-hematologic)
Time Frame: Up to 5 years post-treatment
|
Up to 5 years post-treatment
|
|
Changes of EGFR expression (i.e., EGFR modulation) between buccal smears and bronchial tissue
Time Frame: From baseline up to 5 years post-treatment
|
Agreement will be estimated using the kappa coefficient.
An important aspect of this trial is to identify changes in expression of potential biomarkers between buccal smears and bronchial tissues after induction (neoadjuvant) platinum-based therapy in early-stage , resectable non-small cell lung cancers.
As part of the primary outcome measures, we plan to measure the EGFR expression changes (i.e.
EGFR modulation) between buccal smears and bronchial tissues after induction therapy.
|
From baseline up to 5 years post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of EGFR mutations
Time Frame: Up to 5 years post-treatment
|
The frequency of EGFR mutations in resected tumor specimens following neoadjuvant platinum-based therapy will be evaluated.
|
Up to 5 years post-treatment
|
Evaluation of immune-based biomarkers
Time Frame: Up to 5 years post-treatment
|
The correlation among various continuous and discrete biomarkers will be assessed first by exploratory data analysis using scatter plot matrix, bx plots, BLiP plot, and trellis plots.
Correlation among continuous biomarkers will be estimated by Pearson or Spearman rank correlation coefficient.
The association on discrete biomarkers will be tested by chi-square or Fisher's exact test.
McNamar's test will be applied to test the change of a single discrete biomarker over time.
|
Up to 5 years post-treatment
|
Time to progression
Time Frame: Up to 5 years post-treatment
|
Estimated by Kaplan-Meier method.
The Cox (proportional hazards) model will be fitted to estimate the effect of biomarker and other covariates on survival.
|
Up to 5 years post-treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tina Cascone, MD,PHD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protein Kinase Inhibitors
- Docetaxel
- Erlotinib Hydrochloride
- Cisplatin
Other Study ID Numbers
- 2004-0221 (Other Identifier: M D Anderson Cancer Center)
- NCI-2012-01560 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NCI-2010-00817
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IB Lung Non-Small Cell Carcinoma AJCC v7
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
Roswell Park Cancer InstituteActive, not recruitingStage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage I Non-Small Cell Lung Cancer AJCC v7 | Stage...United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); RefleXion...CompletedStage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage I Lung Cancer | Stage II Lung Cancer | Stage I Non-Small Cell Lung Cancer AJCC v7 | Stage IA Non-Small...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaboratorsActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Canada, Ireland, Peru, South Africa
-
National Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Stage III Lung Adenocarcinoma AJCC v7 | Stage... and other conditionsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingStage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...United States, Guam, Puerto Rico
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyActive, not recruitingStage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
Clinical Trials on Erlotinib Hydrochloride
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
University of California, DavisNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedRecurrent Non-small Cell Lung CancerUnited States
-
Merck Sharp & Dohme LLCCompleted
-
European Organisation for Research and Treatment...CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerFrance, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
-
The Cleveland ClinicUnknownBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedHead and Neck CancerSpain, United States
-
National Cancer Institute (NCI)NCIC Clinical Trials GroupCompletedEndometrial CancerCanada
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedGastric Cancer | Esophageal CancerUnited States, Canada